

## Digital ANA (dANA) - image based

|  |   |           |  |      |      |          |       |      |    |
|--|---|-----------|--|------|------|----------|-------|------|----|
| <b>Accreditation Status:</b>               | <i>accreditation to ISO 17043 pending</i>   |           |  |      |      |          |       |      |    |
| <b>Date Scheme started:</b>                | 2021  |           |  |      |      |          |       |      |    |
| <b>Clinical Applicability:</b>             | Recognition of HEp-2 patterns seen in autoimmune disease in accordance with International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP).  |           |  |      |      |          |       |      |    |
| <b>Analytes:</b>                           | A digital based image programme. Includes identifying the presence and identification of staining patterns in HEp-2 cell lines using the ICAP system<br><b>(DA/601)</b><br><b><i>Multiple digital users can be registered.</i></b>  |           |  |      |      |          |       |      |    |
| <b>Units for Reporting:</b>                | N/A   |           |  |      |      |          |       |      |    |
| <b>Samples Distributed:</b>                | A set of 3 digital images (magnification 1x100, 1x200, 1x400) from healthy donors or patients with autoimmune connective tissue disease.  |           |  |      |      |          |       |      |    |
| <b>Number of Distributions per Year:</b>   | 4   |           |  |      |      |          |       |      |    |
| <b>Number of Samples per Distribution:</b> | 2 digital samples per distribution  |           |  |      |      |          |       |      |    |
| <b>Frequency of Distributions:</b>         | Every 12 weeks as outlined in the <a href="#">Distribution Schedule</a>   |           |  |      |      |          |       |      |    |
| <b>Schedule of Analysis:</b>               | Access to the digital images is via the web and includes the submission of interpretations. Data analysis is commenced 21 days after release of case. Late returns cannot be accepted.  |           |  |      |      |          |       |      |    |
| <b>Data Analysis:</b>                      | Qualitative responses are assessed in terms of MI scoring for each scoring element in relation to the Designated Response.  |           |  |      |      |          |       |      |    |
| <b>Performance Scoring:</b>                | MI scoring  |           |  |      |      |          |       |      |    |
| <b>Criteria of Performance:</b>            | Laboratory performance is classified in terms of OMIS derived from the qualitative responses for: <ul style="list-style-type: none"><li>• HEp-2 Cell Staining</li><li>• Cell location of staining</li><li>• Description of Nuclear staining pattern (Level 1)</li><li>• Description of Nuclear staining pattern (Level 2)</li></ul> over a running analytical window of 4 Distributions (12 months)<br><br>The categories of performance are: <table><tr><td>Total MIS</td><td></td></tr><tr><td>Good</td><td>zero</td></tr><tr><td>Adequate</td><td>1 - 2</td></tr><tr><td>Poor</td><td>&gt;2</td></tr></table> An OMIS of 2 or more for any one analyte will be classed as poor performance | Total MIS |  | Good | zero | Adequate | 1 - 2 | Poor | >2 |
| Total MIS                                  |   |           |  |      |      |          |       |      |    |
| Good                                       | zero  |           |  |      |      |          |       |      |    |
| Adequate                                   | 1 - 2   |           |  |      |      |          |       |      |    |
| Poor                                       | >2  |           |  |      |      |          |       |      |    |
| <b>Persistent Poor Performance:</b>        | Defined as being in the Poor Performance category for two or more successive Distributions  |           |  |      |      |          |       |      |    |